Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Executive Changes (Dec 8, 2025)

Reports
Leadership Changes
Filing Date
Filed December 8, 2025
Period End
December 4, 2025
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed December 8, 2025. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. filed this Form 8-K on December 8, 2025 under Item 5.02 to report a board change.

On December 4, 2025, James Lang was elected to the Company's Board of Directors. He was elected to the class of directors whose terms end at the 2027 annual meeting of stockholders, and he was not initially assigned to any Board committee. Mr. Lang will be compensated under the Company's director compensation program applicable to all non-employee directors, as revised from time to time.

The filing states that this program currently consists of cash retainers for Board and committee service, restricted stock, and stock option awards. The filing refers to the program components as described in the proxy statement for the 2025 Annual Meeting of Stockholders, held on May 1, 2025.

The filing states that there are no arrangements or understandings under which Mr. Lang was elected, and no related person transactions between the Company and Mr. Lang. This is a governance update with no financial figures disclosed in the filing.

Key Highlights

  1. James Lang was elected to Halozyme's Board of Directors on December 4, 2025.
  2. Mr. Lang was elected to the class of directors with terms ending at the 2027 annual meeting of stockholders.
  3. He was not initially assigned to any Board committee.
  4. He will receive compensation under the non-employee director program, which includes cash retainers, restricted stock, and stock option awards.
  5. The filing states there are no arrangements or understandings tied to his election.
  6. The filing states there are no related person transactions between the Company and Mr. Lang.
  7. The filing contains no financial results or guidance figures.

Frequently Asked Questions

  1. Who was added to Halozyme's Board of Directors?

    James Lang was elected to the Board of Directors on December 4, 2025, as a director in the class with terms ending at the 2027 annual meeting of stockholders.

  2. Is Mr. Lang assigned to any Board committees?

    The filing states he was not initially assigned to any Board committee.

  3. How is Mr. Lang compensated?

    He will receive compensation under the director compensation program applicable to all non-employee directors, as revised from time to time. The filing states this currently consists of cash retainers for Board and committee service, restricted stock, and stock option awards, as described in the 2025 proxy statement.

  4. Are there any related party concerns with the appointment?

    The filing states there are no arrangements or understandings under which Mr. Lang was elected, and no related person transactions between the Company and Mr. Lang.